OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	301
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	191
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	184
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	162
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	146
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	144
Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer	138
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	131
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	128
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	128
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	125
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	121
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	117
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	114
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	114
Commentary on oncolytic viruses: past, present, and future	111
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	109
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies	108
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	104
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	102
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	101
iRECIST and atypical patterns of response to immuno-oncology drugs	101
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	100
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	100
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	98

Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	96
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	95
Serotonin transporter SERT: a novel immune checkpoint for CD8 ⁺ T cell antitumor therapy	92
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	91
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	91
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment	90
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	88
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	87
Biomarkers for response to TIL therapy: a comprehensive review	87
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	85
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	83
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	83
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	83
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	82
Is immunotherapy safe and effective in patients with VEXAS syndrome?	82
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	82
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	81
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	80
T-cell tolerant fraction as a predictor of immune-related adverse events	80
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	79
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	79
Single-cell analysis reveals clonally expanded tumor-associated CD57 ⁺ CD8 T cells are enriched in the periphery of patients with metastatic urotheli	78
TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how	77
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	75
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	75
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	75
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	75
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	74
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	74
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	73
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	72
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	72
SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication	72
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	71
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	71
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	70
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	70
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	70
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	70
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	69
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	68
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	68
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy	68